BACKGROUND: Treatment of surgically unresectable recurrence in the head and neck region remains a therapeutic problem with the only curative option being a second course of radiation with a tumouricidal dose. We report initial toxicity and efficacy of charged particle therapy in this situation. METHODS: Treatment-related side-effects of patients treated with charged particle beams for recurrent tumours of the head and neck were prospectively collected and patient data was retrospectively analysed with regard to toxicity and efficacy of the treatment according to CTCAE v. 4.03 and RECIST. RESULTS: Treatment was tolerated well without any severe acute toxicity. In non-chordoma/chondrosarcoma patients, overall response rate was 53.3% at 8 weeks post RT. 4/5 chordoma/chondrosarcoma patients showed no signs of further tumour progression. CONCLUSION: Initial experience of re-irradiation with scanned particle beams in recurrent tumours of the head and neck seems feasible and encouraging. Further follow-up is needed to investigate potential late effects.
BACKGROUND: Treatment of surgically unresectable recurrence in the head and neck region remains a therapeutic problem with the only curative option being a second course of radiation with a tumouricidal dose. We report initial toxicity and efficacy of charged particle therapy in this situation. METHODS: Treatment-related side-effects of patients treated with charged particle beams for recurrent tumours of the head and neck were prospectively collected and patient data was retrospectively analysed with regard to toxicity and efficacy of the treatment according to CTCAE v. 4.03 and RECIST. RESULTS: Treatment was tolerated well without any severe acute toxicity. In non-chordoma/chondrosarcomapatients, overall response rate was 53.3% at 8 weeks post RT. 4/5 chordoma/chondrosarcomapatients showed no signs of further tumour progression. CONCLUSION: Initial experience of re-irradiation with scanned particle beams in recurrent tumours of the head and neck seems feasible and encouraging. Further follow-up is needed to investigate potential late effects.
Authors: Paul B Romesser; Oren Cahlon; Eli D Scher; Eugen B Hug; Kevin Sine; Carl DeSelm; Jana L Fox; Dennis Mah; Madhur K Garg; John Han-Chih Chang; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2016-02-17 Impact factor: 7.038
Authors: Winward Choy; Sergei Terterov; Nolan Ung; Tania Kaprealian; Andy Trang; Antonio DeSalles; Lawrance K Chung; Neil Martin; Michael Selch; Marvin Bergsneider; William Yong; Isaac Yang Journal: J Neurol Surg B Skull Base Date: 2015-08-03
Authors: Rami A El Shafie; Maja Czech; Kerstin A Kessel; Daniel Habermehl; Dorothea Weber; Stefan Rieken; Nina Bougatf; Oliver Jäkel; Jürgen Debus; Stephanie E Combs Journal: Radiat Oncol Date: 2018-05-08 Impact factor: 3.481
Authors: Amy J Xu; Leo Luo; Jonathan E Leeman; Paul B Romesser; Daniel Spielsinger; Christopher Sabol; Todd Waldenberg; Thomas Brinkman; Nadeem Riaz; Sean McBride; Julie Kang; Nancy Lee; Chiaojung Jillian Tsai Journal: Clin Transl Radiat Oncol Date: 2020-04-24
Authors: Mauricio E Gamez; Samir H Patel; Lisa A McGee; Terence T Sio; Mark McDonald; Jack Phan; Daniel J Ma; Robert L Foote; Jean-Claude M Rwigema Journal: Int J Part Ther Date: 2021-06-25